scholarly journals Clinical immunology Glutamine abolishes the TLR4 gene expression levels in pancreatic cancer patients: a preliminary study

2012 ◽  
Vol 4 ◽  
pp. 350-354
Author(s):  
Sylwia Kędziora ◽  
Robert Słotwiński ◽  
Aleksandra Dąbrowska ◽  
Gustaw Lech ◽  
Maciej Słodkowski ◽  
...  
Keyword(s):  
Gene Expression ◽  
Pancreatic Cancer ◽  
Cancer Patients ◽  
Clinical Immunology ◽  
Expression Levels ◽  
Tlr4 Gene ◽  
Preliminary Study ◽  
Gene Expression Levels

scholarly journals Gene Expression Levels as Predictive Markers of Outcome in Pancreatic Cancer after Gemcitabine-Based Adjuvant Chemotherapy

Neoplasia ◽  
2010 ◽  
Vol 12 (10) ◽  
pp. 807-IN8 ◽  
Author(s):  
Hayato Fujita ◽  
Kenoki Ohuchida ◽  
Kazuhiro Mizumoto ◽  
Soichi Itaba ◽  
Tetsuhide Ito ◽  
...  
Keyword(s):  
Gene Expression ◽  
Pancreatic Cancer ◽  
Adjuvant Chemotherapy ◽  
Predictive Markers ◽  
Expression Levels ◽  
Gene Expression Levels

Interaction between smoking history and gene expression levels impacts survival of breast cancer patients

2015 ◽  
Vol 152 (3) ◽  
pp. 545-556 ◽  
Author(s):  
Sarah A. Andres ◽  
Katie E. Bickett ◽  
Mohammad A. Alatoum ◽  
Theodore S. Kalbfleisch ◽  
Guy N. Brock ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Cancer Patients ◽  
Smoking History ◽  
Breast Cancer Patients ◽  
Expression Levels ◽  
Gene Expression Levels

Molecular profiles of appendiceal adenocarcinoma: The UCSD experience.

2013 ◽  
Vol 31 (4_suppl) ◽  
pp. 397-397
Author(s):  
John P. Shen ◽  
Devon Marcus McGee ◽  
Andrew M. Lowy ◽  
Paul Timothy Fanta
Keyword(s):  
Gene Expression ◽  
Colon Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Braf V600e ◽  
Appendiceal Cancer ◽  
Expression Levels ◽  
Appendix Cancer ◽  
Tumor Types ◽  
Gene Expression Levels

397 Background: Appendix cancer is rare, which precludes its study in randomized trials. As such, no evidence-based guidelines currently exist regarding the optimum systemic therapy for this disease entity. Typically, these patients are treated with regimens for colorectal carcinoma. Previous studies have shown high intra-tumoral mRNA levels of EGFR were significantly associated with response to irinotecan based chemotherapy, and that mucinous colorectal cancer overexpresses markers of resistance to 5-FU and oxaliplatin. We examined pharmacogenomics markers for appendiceal cancer and colon cancer to understand underlying similarities and differences between these tumor types. Methods: Intratumoral gene expression levels were assessed from paraffin-embedded tissue samples, using laser capture microdissection and quantitative real-time PCR from 69 colorectal and 34 appendiceal adenocarcinomas. A retrospective chart review was performed to correlate gene expression with overall survival. KRAS and BRAF mutational analyses and gene expression levels of ERCC1, TS, and EGFR were correlated with overall survival. Results: Appendiceal tumors had significantly higher expression of EGFR, (2.66 vs 1.4, p<.0001). No BRAF V600E mutations were found in the appendiceal tumors, incidence was 8.97% of the colon patients. UPDATE: In appendix cancer, KRAS mutations were noted in 65.5% of patients, there were no BRAF mutations. Median ERCC1, TS, EGFR, and VEGFR2A expression was 1.4, 1.21, 1.57, 2.19 respectively. Patients with metastatic appendiceal cancer had a significantly longer median OS than metastatic colon patients, (113 mo vs 43.9 mo, p = .0154). For appendiceal cancer patients, there was no significant correlation between any of the biomarkers and OS, although the sample size was underpowered for such an analysis. Conclusions: Metastatic appendiceal cancer patients have significantly better outcomes than metastatic colon cancer patients. Molecular analyses reveal significant differences between these tumor types. Further molecular study of appendiceal cancer is needed, as this study and others suggest fundamental differences in biology from colon cancer.

scholarly journals Post-treatment recovery of suboptimal DNA repair capacity and gene expression levels in colorectal cancer patients

2014 ◽  
Vol 54 (9) ◽  
pp. 769-778 ◽  
Author(s):  
Jana Slyskova ◽  
Francesca Cordero ◽  
Barbara Pardini ◽  
Vlasta Korenkova ◽  
Veronika Vymetalkova ◽  
...  
Keyword(s):  
Gene Expression ◽  
Colorectal Cancer ◽  
Dna Repair ◽  
Cancer Patients ◽  
Post Treatment ◽  
Repair Capacity ◽  
Expression Levels ◽  
Dna Repair Capacity ◽  
Colorectal Cancer Patients ◽  
Gene Expression Levels

Penalized differential pathway analysis of integrative oncogenomics studies

2014 ◽  
Vol 13 (2) ◽  
Author(s):  
Wessel N. van Wieringen ◽  
Mark A. van de Wiel
Keyword(s):  
Gene Expression ◽  
Cancer Patients ◽  
Copy Number ◽  
Model Parameters ◽  
Integrative Genomics ◽  
Dna Copy Number ◽  
Expression Levels ◽  
Copy Number Aberrations ◽  
Dna Copy Number Aberrations ◽  
Gene Expression Levels

AbstractThrough integration of genomic data from multiple sources, we may obtain a more accurate and complete picture of the molecular mechanisms underlying tumorigenesis. We discuss the integration of DNA copy number and mRNA gene expression data from an observational integrative genomics study involving cancer patients. The two molecular levels involved are linked through the central dogma of molecular biology. DNA copy number aberrations abound in the cancer cell. Here we investigate how these aberrations affect gene expression levels within a pathway using observational integrative genomics data of cancer patients. In particular, we aim to identify differential edges between regulatory networks of two groups involving these molecular levels. Motivated by the rate equations, the regulatory mechanism between DNA copy number aberrations and gene expression levels within a pathway is modeled by a simultaneous-equations model, for the one- and two-group case. The latter facilitates the identification of differential interactions between the two groups. Model parameters are estimated by penalized least squares using the lasso (

scholarly journals Changes in VEGF and HIF 1α gene expression levels as potential diagnostic/prognostic markers in liquid biopsies on breast cancer patients

2019 ◽  
Vol 33 (S1) ◽  
Author(s):  
Carlos Henrique Foncesca Peiró ◽  
Jéssica Freitas Araújo Encinas ◽  
Glauco Sérgio Avelino Aquino ◽  
Glaucia Luciano Veiga ◽  
Matheus Moreira Perez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Cancer Patients ◽  
Prognostic Markers ◽  
Breast Cancer Patients ◽  
Liquid Biopsies ◽  
Expression Levels ◽  
Gene Expression Levels

VEGF and VEGFR1 gene expression levels and tumor recurrence in adjuvant colon cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 4040-4040 ◽  
Author(s):  
Y. Ning ◽  
G. Lurje ◽  
K. Danenberg ◽  
J. Cooc ◽  
D. Yang ◽  
...  
Keyword(s):  
Gene Expression ◽  
Colon Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Tumor Recurrence ◽  
Stage Ii ◽  
Tissue Samples ◽  
Expression Levels ◽  
Stage Iii Colon Cancer ◽  
Gene Expression Levels

4040 Background: Tumor recurrence after curative resection is still a major problem in the management of adjuvant colon cancer, with recurrence rate approximately 30–40%. Identifying molecular markers for tumor recurrence is critical for successfully selecting patients who are more likely to benefit from adjuvant chemotherapy. Our group previously showed that angiogenesis gene polymorphisms (VEGF and IL-8) may associated with tumor recurrence in adjuvant colon cancer (Lurje Ann Oncol, 2008). Here we tested the hypothesis whether gene expression levels of angiogenesis pathway (COX-2, EGFR, VEGF, VEGFR1, VEGFR2 and IL-8) could also predict the risk of tumor recurrence in stage II and III colon cancer patients treated with adjuvant chemotherapy. Methods: Tissue samples from 140 adjuvant colon cancer patients (69 females and 71 males with a median age of 59 years; range=28–86) were available for gene expression assays. These tissue samples were obtained at the University of Southern California/Norris Comprehensive Cancer Center (USC/NCCC) and LAC+USC medical center between 1999 and 2006. Sixty-three patients had stage II and 77 had stage III colon cancer. The median follow-up was 5.4 years (range=2.0–16.8). 51 of 140 patients (36.4%) developed tumor recurrence with a 5-year probability of 0.28 ± 0.06 for stage II and 0.40 ± 0.06 for stage III colon cancer patients. mRNA was extracted from laser-capture-microdissected tumor tissue. After cDNA was prepared by reverse transcription, quantitation of the candidate genes and an internal reference gene (ß-actin) was performed using a fluorescence-based real-time detection method (TaqMan). Results: We found VEGF and VEGFR1 gene expression levels independently significantly associated with time to tumor recurrence in adjuvant colon cancer patients. Patients with lower VEGF gene expression and lower VEGFR1 gene expression levels had significantly longer time to tumor recurrence compared to those with higher VEGF and higher VEGFR1 gene expression levels (p<0.05, log-rank test). Conclusions: VEGF and VEGFR1 gene expression levels may predict tumor recurrence risk in adjuvant colon cancer patients. Our exploratory data warrant future confirmatory trial. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document